Citations

Clear

9383 citation(s) found for "Thomas, PS".

A 75-year-old man with cognitive impairment and gait changes
Lippa, Carol F. , Parisi, Joseph E. , Boeve, Bradley F. , Keegan, B. Mark

Mayo Clinic

Neurology | September 10, 2007 | Volume: 69 | Issue: 11 | Pages: 1183-1189

10.1212/01.wnl.0000284706.20956.c7 | PMID 17846418 Get It

Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
Cerhan, James R. , Ansell, Stephen M. , Fredericksen, Zachary S., Liebow, Mark , Call, Timothy G. , Cunningham, Julie M. , Wang, Alice H., Liu‐Mares, Wen, Macon, William R. , Jelinek, Diane F., Kay, Neil E. , Doǧan, Ahmet , Witzig, Thomas E. , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R

Mayo Clinic

Blood | September 8, 2007 | Volume: 110 | Issue: 13 | Pages: 4455-4463

10.1182/blood-2007-05-088682 | PMID 17827388 Get It

Smaller-scale evaluations suggest that common genetic variation in candidate genes related to immune function may predispose to the development of non-Hodgkin lymphoma (NHL). We report an analysis of variants within genes associated with immunity and inflammation and risk of NHL using a panel of 9412 single-nucleotide polymorphisms (SNPs) from 1253 genes in a study of 458 patients with NHL and 484 frequency-matched controls. We modeled haplotypes and risk of NHL, as well as the main effects for all independent SNPs from a gene in multivariate logistic regression models; we separately report results for nonsynonymous (ns) SNPs. In gene-level analyses, the strongest findings (P ≤ .001) were for CREB1, FGG, MAP3K5, RIPK3, LSP1, TRAF1, DUSP2, and ITGB3. In nsSNP analyses, the strongest findings (P ≤ .01) were for ITGB3 L59P (odds ratio [OR] = 0.66; 95% confidence interval [CI] 0.52-0.85), TLR6 V427A (OR = 5.20; CI 1.77-15.3), SELPLG M264V (OR = 3.20; CI 1.48-6.91), UNC84B G671S (OR = 1.50; CI 1.12-2.00), B3GNT3 H328R (OR = 0.74; CI 0.59-0.93), and BAT2 V1883L (OR = 0.64; CI 0.45-0.90). Our results suggest that genetic variation in genes associated with immune response (TRAF1, RIPK3, BAT2, and TLR6), mitogen-activated protein kinase (MAPK) signaling (MAP3K5, DUSP2, and CREB1), lymphocyte trafficking and migration (B3GNT3, SELPLG, and LSP1), and coagulation pathways (FGG and ITGB3) may be important in the etiology of NHL, and should be prioritized in replication studies.
Strong Evidence of a Genetic Determinant for Mammographic Density, a Major Risk Factor for Breast Cancer
Vachon, Celine M. , Sellers, Thomas A. , Cunningham, Julie M. , Hilker, Christopher A., Smalley, Regenia L., Schaid, Daniel J. , Kelemen, Linda E. , Vachon, Celine M. , Carlson, Erin E. , Couch, Fergus J. , Pankratz, V. Shane

Mayo Clinic

Cancer Research | September 5, 2007 | Volume: 67 | Issue: 17 | Pages: 8412-8418

10.1158/0008-5472.can-07-1076 | PMID 17804758 Get It

Abstract Increased mammographic density (MD), the proportion of dense tissue visible on a mammogram, is a strong risk factor for breast cancer, common in the population and clusters in families. We conducted the first genome-wide linkage scan to identify genes influencing MD. DNA was obtained from 889 relatives (756 women, 133 men) from 89 families. Percent MD was estimated on 618 (82%) female family members using a validated computer-assisted thresholding method. The genome-wide scan included 403 microsatellite DNA markers with an average spacing of 9 cM. Fine mapping of a region of chromosome 5p (5p13.1-5p15.1) was done using 21 additional closely spaced DNA markers. Linkage analyses were conducted to quantify the evidence for a gene responsible for MD across the genome. The maximum log odds for linkage (LOD) score from the genome-wide scan was on chromosome 5p (LOD = 2.9, supporting linkage by a factor of 102.9 or 794 to 1) with a 1-LOD interval spanning 28.6 cM. Two suggestive regions for linkage were also identified on chromosome 12 (LOD = 2.6, 1-LOD interval of 14.8 cM; and LOD = 2.5, 1-LOD interval of 17.2 cM). Finer mapping of the region surrounding the maximum LOD on chromosome 5p resulted in stronger and statistically significant evidence for linkage (LOD = 4.2) and a narrowed 1-LOD interval (13.4 cM). The putative locus on chromosome 5p is likely to account for up to 22% of variation in MD. Hence, 1 or more of the 45 candidate genes in this region could explain a large proportion of MD and, potentially, breast cancer. [Cancer Res 2007;67(17):8412–8]
Association of Plasma Resistin With Glomerular Filtration Rate and Albuminuria in Hypertensive Adults
Ellington, Allison A., Malik, A. Rauoof , Klee, George G., Turner, Stephen T. , Rule, Andrew D. , Mosley, Thomas H. , Kullo, Iftikhar J.

Mayo Clinic

Hypertension | September 5, 2007 | Volume: 50 | Issue: 4 | Pages: 708-714

10.1161/hypertensionaha.107.095257 | PMID 17785630 Get It

Resistin, a recently discovered proinflammatory cytokine, has been variably associated with insulin resistance, inflammation, and renal dysfunction. We investigated the association of plasma resistin with estimated glomerular filtration rate and albuminuria in 1575 hypertensive adults without known coronary heart disease or stroke (857 blacks and 718 non-Hispanic whites). Resistin was measured by a solid phase sandwich immunoassay, estimated glomerular filtration rate was estimated from serum creatinine, and albuminuria was expressed as urine albumin:creatinine ratio. After adjustment for coronary heart disease risk factors (age, sex, body mass index, smoking history, systolic blood pressure, diabetes, and total and high-density lipoprotein cholesterol) and use of renin-angiotensin blockers and statins, higher plasma resistin levels were associated with lower estimated glomerular filtration rate in both ethnic groups (each P <0.0001); the association remained significant after further adjustment for a marker of insulin resistance (homeostasis model assessment for insulin resistance) and a marker of inflammation (plasma C-reactive protein) and was seen in subjects with and without diabetes (each P <0.0001) in both ethnic groups. Higher plasma resistin levels were associated with a higher urine albumin:creatinine ratio in black subjects with diabetes ( P <0.0001) and non-Hispanic white subjects with diabetes ( P =0.032), independent of coronary heart disease risk factors, hypertension medication use, and statin use; the association remained significant after additional adjustment for homeostasis model assessment for insulin resistance and C-reactive protein. In adults with hypertension, higher circulating resistin levels were associated with a lower estimated glomerular filtration rate and with increased urine albumin:creatinine ratio in the presence of concomitant diabetes. This association was independent of coronary heart disease risk factors and markers of insulin resistance and inflammation.
Influence of Tiotropium on Symptoms of Chronic Obstructive Pulmonary Disease in a Patient With Chronic Heart Failure
Olson, Thomas P. , Johnson, Bruce D.

Mayo Clinic

Circulation Journal | September 3, 2007 | Volume: 71 | Issue: 5 | Pages: 802-803

10.1253/circj.71.802 | PMID 17476791 Get It

Book Review: Somatic Dysfunction in Osteopathic Family Medicine by Kenneth E. Nelson and Thomas Glonek Baltimore: Lippincott Williams & Wilkins; 2006; $49.95; ISBN-10: 1405104759
Brault, Jeffrey S.

Mayo Clinic

American Journal of Lifestyle Medicine | August 29, 2007 | Volume: 1 | Issue: 5 | Pages: 411-411

10.1177/1559827607304522 Get It

Zolmitriptan nasal spray in the acute treatment of cluster headache
Rapoport, Alan M. , Mathew, N. T., Silberstein, SD, Tepper, SJ , Sheftell, Fred D., Bigal, Marcelo E. , Dodick, David W.

Mayo Clinic

Neurology | August 27, 2007 | Volume: 69 | Issue: 9 | Pages: 821-826

10.1212/01.wnl.0000267886.85210.37 | PMID 17724283 Get It

Aortic Diameter ≥5.5 cm Is Not a Good Predictor of Type A Aortic Dissection
Pape, Linda, Tsai, Thomas T., Oh, Jae K. , Evangelista, Arturo , Fattori, Rossella , Meinhardt, Gabriel, Trimarchi, Santi , Bossone, Eduardo , Cooper, Jeanna V., Froehlich, James B. , Isselbacher, Eric M. , O’Gara, Patrick T. , Suzuki, Toru , Nienaber, Christoph , Eagle, Kim A. , Bossone, Eduardo

Mayo Clinic

Circulation | August 21, 2007 | Volume: 116 | Issue: 10 | Pages: 1120-1127

10.1161/circulationaha.107.702720 | PMID 17709637 Get It

Background— Studies of aortic aneurysm patients have shown that the risk of rupture increases with aortic size. However, few studies of acute aortic dissection patients and aortic size exist. We used data from our registry of acute aortic dissection patients to better understand the relationship between aortic diameter and type A dissection. Methods and Results— We examined 591 type A dissection patients enrolled in the International Registry of Acute Aortic Dissection between 1996 and 2005 (mean age, 60.8 years). Maximum aortic diameters averaged 5.3 cm; 349 (59%) patients had aortic diameters <5.5 cm and 229 (40%) patients had aortic diameters <5.0 cm. Independent predictors of dissection at smaller diameters (<5.5 cm) included a history of hypertension (odds ratio, 2.17; 95% confidence interval, 1.03 to 4.57; P =0.04), radiating pain (odds ratio, 2.08; 95% confidence interval, 1.08 to 4.0; P =0.03), and increasing age (odds ratio, 1.03; 95% confidence interval, 1.00 to 1.05; P =0.03). Marfan syndrome patients were more likely to dissect at larger diameters (odds ratio, 14.3; 95% confidence interval, 2.7 to 100; P =0.002). Mortality (27% of patients) was not related to aortic size. Conclusions— The majority of patients with acute type A acute aortic dissection present with aortic diameters <5.5 cm and thus do not fall within current guidelines for elective aneurysm surgery. Methods other than size measurement of the ascending aorta are needed to identify patients at risk for dissection.
Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy
Czuczman, Myron S., Emmanouilides, Christos, Darif, Mohamed, Gordon, Leo I. , Revell, Stephen, Vo, Katie D. , Molina, Arturo , Witzig, Thomas E. , Gordon, Leo I

Mayo Clinic

Journal of Clinical Oncology | August 20, 2007 | Volume: 25 | Issue: 27 | Pages: 4285-4292

10.1200/jco.2006.09.2882 | PMID 17709799 Get It

Purpose To investigate the incidence of treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute myelogenous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy. Patients and Methods Analysis of the incidence of t-MDS and t-AML in 746 patients with non-Hodgkin's lymphoma (NHL) treated with the ibritumomab tiuxetan regimen in registration and compassionate-use trials between 1996 and 2002. Results Nineteen patients (2.5%) developed t-MDS or t-AML at a median follow-up of 4.4 years (range, 0 to 9.3). These malignancies were diagnosed at a median of 5.6 years (range, 1.4 to 13.9) after the diagnosis of NHL and 1.9 years (range, 0.4 to 6.3) after radioimmunotherapy. The annualized rates were 0.3% per year after the diagnosis of NHL and 0.7% per year after treatment. Most patients with t-MDS or t-AML had multiple cytogenetic aberrations, commonly on chromosomes 5 and 7, suggesting an association with previous exposure to chemotherapy. Conclusion Analysis of data from patients in registration and compassionate-use trials suggests that the annualized incidences of t-MDS and t-AML are consistent with that expected in patients with NHL who have had extensive previous chemotherapy treatment and do not appear to be increased after treatment with the ibritumomab tiuxetan regimen. Cytogenetic testing before treatment with radioimmunotherapy may identify existing chromosomal abnormalities in previously treated patients, particularly those who have been treated with alkylating agents and purine nucleoside analogs and would be at higher risk for t-MDS or t-AML.
Histopathological Changes Associated With Dextranomer/Hyaluronic Acid Injection for Pediatric Vesicoureteral Reflux
Routh, Jonathan C. , Ashley, Richard , Sebo, Thomas J., Vandersteen, David R. , Slezak, Jeffrey M., Reinberg, Yuri, Routh, Jonathan C

Mayo Clinic

Journal of Urology | August 18, 2007 | Volume: 178 | Issue: 4S | Pages: 1707-1710

10.1016/j.juro.2007.03.165 | PMID 17707018 Get It